Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes |
May 2023 |
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
Real-World Study of the Burden of Myelodysplastic Syndromes in Patients and Their Caregivers in Europe and the United States |
Dec 2024 |
Oncology and Therapy |
Myelodysplastic Syndromes (MDS) |
Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study |
Nov 2024 |
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria |
May 2021 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes |
Apr 2024 |
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis |
Jun 2019 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria |
Sep 2019 |
Therapeutic Advances in Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading? |
Dec 2020 |
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS) |
Raising the bar for lower-risk myelodysplastic syndromes |
Jun 2023 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
Raising the bar for lower-risk myelodysplastic syndromes |
Apr 2023 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |